Advertisment
Novartis to present long-term data on Kesimpta and neuroscience pipeline at AAN 2025
Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcomes and safety data from the ALITHIOS open-label extension trial of Kesimpta® (ofatumumab) in people with relapsing multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego from April 5-9, 2025. Additional data on Kesimpta and pipeline assets including remibrutinib and iptacopan will also be highlighted.
“We look forward to sharing several clinical and real-world studies on Kesimpta in people living with RMS as well as additional studies across our neuroscience portfolio,” said Norman Putzki, M.D., Ph.D., Development Unit Head, Neuroscience & Gene Therapy, Development, Novartis. “As always, we are excited to attend the AAN annual meeting and discuss the latest developments in neuroscience as we work to address some of the most pressing challenges for people living with neurological conditions.”
Data to be presented at AAN include:
| Abstract Title | Abstract Number/ Presentation Details |
| Kesimpta | |
| Continuous Ofatumumab Treatment Up to 7 Years Shows a Consistent Safety Profile and Delays Disability Progression in People with Relapsing Multiple Sclerosis | P7.016
Monday, April 7 5:00 – 6:00 PM PT |
| Long-Term Ofatumumab Treatment Over 6 Years Did Not Increase the Risk of Serious Infections | P8.017
Tuesday, April 8 8:00 – 9:00 AM PT |
| Longer-Term (up to 6 Years) Efficacy and Safety of Ofatumumab in People with Non-highly Active MS Early in the Disease Course | P11.003
Wednesday, April 9 8:00 – 9:00 AM PT |
| Real-World Data on Ofatumumab as First-line Treatment in Early RMS (AIOLOS Study) | P7.013
Monday, April 7 5:00 – 6:00 PM PT |
| Pipeline Molecules | |
| Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Participants | P12.003 Wednesday, April 9 11:45 AM – 12:45 PM PT |
| Efficacy and Safety of Iptacopan in Patients with Generalized Myasthenia Gravis: Study Design | P7.027
Monday, April 7 5:00 – 6:00 PM PT |
| Biomarkers | |
| Prognostic Value of Baseline Serum Neurofilament Light Chain (sNfL) Levels in People with Relapsing Multiple Sclerosis by Prior Treatment Status and DMT Type | P5.009
Monday, April 7 8:00 – 9:00 AM PT |
| NeofiLos – sNfL in Daily Clinical Routine | P5.015
Monday, April 7 8:00 – 9:00 AM PT |
Product Information
For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products.
